Study on the Biomarker of First-line Immunotherapy Combined With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03706326` - CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer	Phase 1/Phase 2
Recruiting	`NCT05425472` - A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer	Phase 2
Completed	`NCT03691090` - Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer	Phase 3

See also

Status

Clinical Trial

Phase

Recruiting

NCT03706326 - CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Phase 1/Phase 2

Recruiting

NCT05425472 - A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Phase 2

Completed

NCT03691090 - Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05174156
Study type	Interventional
Source	Sixth Affiliated Hospital, Sun Yat-sen University
Contact	Hongying Liao, Professor
Phone	+86 13928845885
Email	hylmed1996@126.com
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2022
Completion date	December 31, 2023

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms